Navigation Links
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
Date:4/11/2011

herapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  

The vaccine is designed to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells. The antibodies are expected to seek out and eliminate residual circulating cancer cells and micrometastases. The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from MSKCC in 2008.  

Additional information may be obtained by following the link to the clinicaltrials.gov website.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is creating a pipeline of monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company i
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SEGUNDO, Calif. , July 30, 2014 /PRNewswire/ ... contractor on the Fully Integrated Lifecycle Mission Support ... and Space Administration (NASA). Under the terms of ... Ames Research Center at Moffett Field, Calif. In ... support for bioscience flight development projects on the ...
(Date:7/30/2014)... July 30, 2014. Applied DNA ... that provides DNA-based authentication and security solutions and services, ... of Life Sciences, a newly created position, with a ... will lead APDN’s drive to build its business in ... healthcare customers, provide guidance to APDN’s R&D efforts, and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vycom announces ... of products, designed to meet Factory Mutual (FM) 4910 ... materials such as wet benches, process tools, fume hoods, ... safety and damage to semiconductor wafers used in electronic ... a flame-retardant PVC solution with excellent workability and superior ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Immunodiagnostics Markets: US, Europe, Japan Product ... for Instrumentand Reagent Suppliers ...
... 25, 2011 Practice Fusion , the ... working with Microsoft,s DataMarket on the Windows Azure Marketplace ... developers and researchers is part of the Health 2.0 ... Developer Challenge with the support of the Chief Technology ...
... Jan. 25, 2011 Reportlinker.com announces that ... in its catalogue: Future ... of Emerging Reimbursement, Technological and Market Trends ... How will the ...
Cached Biology Technology:Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers 2Practice Fusion Invites Health Researchers to 'Analyze This!' Contest on Windows Azure 2Practice Fusion Invites Health Researchers to 'Analyze This!' Contest on Windows Azure 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2
(Date:7/30/2014)... infection could be as simple as inserting a medicated, ... of Washington bioengineers have discovered a potentially faster way ... contracting HIV. Their method spins the drug into silk-like ... releasing higher doses of the drug than possible with ... "This could offer women a potentially more effective, discreet ...
(Date:7/30/2014)... climate threaten some of the world,s most rare ... seed collections to save the seeds in banks ... genetic diversity., For decades, these seed collections have ... one-size-fits-all approach for how many seeds to gather, ... of species, pollination mode, growth habitat and population ...
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3Saving seeds the right way can save the world's plants 2
... have charted the path of insulin action in cells in ... for understanding what goes wrong in diabetes. The ... from Sydney,s Garvan Institute of Medical Research, is now published ... Cell Metabolism . First discovered in 1921, the insulin ...
... (MAY 20, 2013) University of Minnesota Medical School ... in partnership with the University,s Brain Tumor Program, have ... sheath tumors (MPNST) that allow them to discover new ... The research was published this week in the ...
... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ...
Cached Biology News:Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: